AI Summary
Artificial intelligence is accelerating drug development timelines and enabling greater automation in early-stage pharmaceutical research. A recent TD Cowen survey of biopharma companies reveals that AI adoption is reshaping how the industry approaches drug discovery and development.
Artificial intelligence is dramatically speeding up drug development — and a proprietary survey shows how it's priming a bigger automation push that's changing the trajectory of early stage pharma research.Why it matters: The TD Cowen survey of 80 biopharma leaders and insiders finds AI…
Full story reconstructed from Biztoc.com. Formatting and media may differ from the original.
View original at Biztoc.com